Leadership
-
Abhinav Bindra on why winning isn't everything
For India to take a leap into developing sport further, we need to treat it as a social culture, and not just a pursuit for medals, India's first individual gold medallist writes
-
AK Bhattacharya on how to future-proof India against shocks
The Trump disruption is an opportunity to build consensus on the need for wide-ranging reforms and their execution, the editorial director of Business Standard, and author, writes
-
From markets to mindsets: The transformative power of disruptions
For the Anniversary Special this year, Forbes India invited industry stalwarts to weigh in on how disruptions can be opportunities for renewal and growth
-
To grow our market share, we need to bring in more products: Piyush Arora of Volkswagen-Skoda India
The MD & CEO of Volkswagen-Skoda India talks about gaining market share in India, the significance of safety features, and investing Rs 10,000 crore over the next decade
-
We're choosing our own battles: Axis Bank's Amitabh Chaudhry
Chaudhry, who had announced while taking over as CEO his ambition of moving the needle in Axis Bank's position, says "if we create the right platforms, keep adding and building on it over a period of time, we can get there"
-
How Axis absorbed Citi's consumer business
It was worth the time and effort, Axis Bank's CEO and MD Amitabh Chaudhry tells Forbes India, and the move pit the bank across the spectrum
-
Amitabh Chaudhry's game plan: Can Axis bank beat HDFC Bank, ICICI Bank?
Under Amitabh Chaudhry, Axis Bank is focusing on leadership in select areas and identifying growth engines. Can he chew all he is biting off?
-
Virologist Michael Taylor volunteers help to cancer patients. His task: Picking health care stocks
Private businesses that give away all profits and also succeed as businesses are scarce; An eleemosynary aim would seem to be even more out of place on Wall Street, where "greed is good" is the mantra
-
Kailera: Betting on China's R&D for the next weight-loss miracle drug
It used to be that Chinese drug development was largely about creating "me too" drugs for the local market. But over the past 10 years, with Beijing focussed on building a native biotech industry, US-trained Chinese scientists have returned home and started innovating instead of mimicking
-
15 years and 3 unicorns: Will Bhavish Aggarwal's disruptive run continue?
Aggarwal made his debut on the Forbes World's Billionaires List this year with a personal wealth of $2 billion, almost a decade and a half since he first set out to build his own business
-
I'm determined. I'm not passionate: Dilip Shanghvi
Sun Pharma chairman and managing director Dilip Shanghvi reveals the secrets behind his leadership tenets of research and acquisition in an interview with Forbes India. He says his weight loss molecule, undergoing trials, can be a blockbuster